(secondQuint)Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer.

 This is a prospective, multi-center, randomized and controlled study.

 Advanced lung cancer patients without venous thromboembolism(VTE) are included.

 The selected patients were randomized into A and B groups.

 Group A: Nadroparin given during hospitalization, 0.

4mL, subcutaneously, qid; Group B: Nadroparin given by long-term, 0.

4mL, subcutaneously, qid.

 The incidence of VTE , the risks of bleeding and overall survival in two groups of patients are studied at different time points.

.

 Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer@highlight

To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.

